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treated with double antiplatelet therapy for 3 months. Results angiographic success was 
obtained in all cases. During the hospital there were no death or repeat revasculariza- 
tions. Non Q-wave myocardial infarction (MI) occurred in 2 (2%) cases in the control arm 
(p=n.s.). After 1 months, no patient died. One patients in the estrogen arm had a non-Q 
wave MI 3 days after the procedure and target lesion revascularization with re-PTCA was 
repeated. All the patients have been scheduled for a 6-month angiographic FU that will 
be available at the time of presentation.Conclusions Stenting lesions on native coronary 
arteries with the estrogen coated stents is safe and is associated with high procedural 
success rate. In hospital course and i-month FU Indicate that estrogen coating stents do 
not seem to increase the risk of acute or sub-acute stent thrombosis compared to bare 
metal stent. The efficacy of this therapy in reducing restenosis rate will be assessed 
when the 6-months angiographic FU results will be available. 
1150-182 Vessel Size, Stent Strut Thickness, and Restenosis 
After Coronary Stem Placement: A Subgroup Analysis 
of the Randomized ISAR-STEREO-2 Trial 
Helmut Schiihlen, Adnan Kastrati, Julinda Mehilli, Jdrg Hausleiter. Jiirgen Pache, Josef 
Dirschinger, Albert Schbmig, Deutsches Herzzentrum. Munich, Germany, 1. Med. Klinik 
rechts der Isar, Munich, Germany 
1150-l 80 Stent-Based Programmable Erodable Polymer Drug 
Release Systems Are Nontoxic in Porcine Arteries 
Douqal McClean Saibal Kar. Taku Honda, Michael C. Fishbein, Neal L. Eigler, Frank 
Litvack. Cedars-Sinai Medical Center, Los Angeles, CA 
Potential drugs for vascular delivery have variable kinetic release requirements. Some 
first generation drug eluting stents have utilized non-erodable polymers and fixed kinet- 
ics, which may be responsible for late malapposition and restenosis. Bioerodable poly- 
mers positioned within the volume of a stent strut may be metabolized without tissue 
toxicity or malapposition. We evaluated configurations of the Conor stent with differing 
polymer volumes and degradation rates for restenosis and tissue toxicity. 
Methods and Results: The Conor stew has honey-combed metallic strut elements that 
contain automated programmable inlaid layers of bioerodable Polylactide-co-glycolide 
(PLGA). Degradation rates were manipulated by altering the PLGA co-monomer ratio 
and molecular weight. Three low volume PLGA groups with different in-vitrodegradation 
rates (21 to 180 days), one high volume PLGA group (21 days), and bare metal stent 
controls were randomly implanted !n the LAD, RCA and superficial femoral arteries (n=40 
stents) in a 30 day porcine model (n=12 pigs). Mean coronary injury scores (range: 1.1 to 
1.4) did not differ between the five groups. Tissue sections preserving metal and polymer 
architecture showed small but significant differences in polymer degradation rate (89% 
vs 78% in fast vs slow groups, pcO.05). Increasing the polymer volume 4-fold slowed the 
degradation rate to near zero. Blinded histologic scoring showed a neoendothelium, min- 
imal inflammation, foreign body reaction or neointimal fibrin and complete healing in all 
groups. NO medial necrws or stent strut malapposition was seen. Quantitative angiogra- 
phy and histomorphometry showed no difference in restenosis parameters versus bare 
metal controls. 
6ackground:The ISAR-STEREO-2 tnal has shown that stent strut thickness has a sig- 
nificant Impact on long-term outcome, with lower restenosis rates for thinner strut stents. 
This effect was seen in a comparison of 2 stents with different design, the thin-strut 
Guidant RX MultiLink and the thick-strut Cordis 8X Veloccty Small vessels (<2.8mm) 
have higher restenosis rates, and although some trials in small vessels have shown a 
significantly lower restenosis rate after stenting compared to PTCA, others have failed to 
show such benefit, including the ISAR-SMART trial using the MultiLink. Goal of the 
present analysis was therefore to differentlate the results of ISAR-STEREO-2 with 
respect to vessel size. 
Methods: All 611 patients randomized I” ISAR-STEREO-2 were included in this analy- 
sis. Results for patients with target vessels <2.8mm (n=262) were compared to those 
with large vessels (Z2.8mm; n=349). 
Results: Baseline clinical and angiographic characteristics did not differ significantly 
between the 2 groups. The primary end point of ISAR-STEREO-E, angiographic resteno- 
sis rate at 6 mo., is illustrated in the graph. 
m MultiLink KIl Velocity 
Conclusions: PLGA degradation rates are controllable but very less than predlcted in- 
vitro and are volume dependent. Erodable PLGA polymers positioned within the steni 
struts are non toxic and suitable for the controlled elution of bioactive substances. 
0 
1150-181 Stent Coated With Nitroxyl Groups for Reduction of 
Neointimal Hyperplasia in a Porcine Coronary Stent 
Model 
e2.8mm >2.8mm 
Yanminq Huanq, Xiaoshun Liu, Shengqiao Li, Lan Wang, Eric Verbeken. Ivan De 
Scheerder, University of Leuven, Leuven. Belgium 
Background: Coronary stent surface modification can improve the biocompatibility of a 
stent. Nrtroxides have shown a wide range of biological effects like suppressing free rad- 
ical driven reactions to maintain cell functions. The objectives of this study was to evalu- 
ate the efficacy of a biodegradable polymer coated stent loaded with nitroxyl groups on 
in-stent neomtimal hyperplasia. 
Methods: Bare stainless steel stents (Genie stents, Blue Medical Devices, The Nether- 
lands), loaded 50% (W%) nitroxyl groups ( Tempo Amine, Blue Medical Devices, The 
Netherlands) biodegradable elastomeric poly(ester-amide)(co-PEA) polymer dipcoated 
stents and control polymer coated stents were randomly implanted into porcine coronary 
arteries. Arterial segments were selected to achieve a balloon to artery ratio 1.5-l .2:1. Al 
5 days (4 stents for each group) and 6 weeks (bare n=8, both polymer coated and 50% 
Tempo loaded stents n=16) follow-up, histomorphometric analysis was performed on 
proximal, middle and distal parl of each stent segment. 
Results: Histomorphometric analysis showed that the bare stems, polymer-coated stents 
and Tempo loaded stents elicited a stmilar tissue response at 5 days follow-up. At 6 
weeks follow-up, the peri-strut inflammation of the polymer coated stents (1.03+0.06 vs 
1.09+0.14, P<O.OS) and Tempo loaded stents(l.O2+0.05 vs 1.09*0.14, PcO.01) were 
significantly lower than the bare stents. Arterial injury of bare stents was significantly 
higher than the polymer coated stems (0.33eO.21 vs 0.62iO.46, PcO.01) and Tempo 
loaded stents (0.34+0.23 vs 0.62+0.46,P<O.O1). Compared to the bare stents, the neoin- 
timal hyperplasis. and area stenosis of polymer coated stents (1.41?0.61 vs 1.78kO.79 
mm2; 25+11 vs 35+23 %; PqO.05) and Tempo loaded stems (1.27t0.42 vs 1.78*0.79 
mm2; 24*8 vs 35+23 %; P<O.Ol) were significantly decreased. The neointimal hyperpla- 
sia of Tempo loaded stems was the lowest. 
Conclusion: These co-PEA polymer stent coating showed a biocompatible performance 
and could decrease the neointimal hyperplasia at 6 weeks follow-up compared to bare 
stents. Loading of the polymer wth nitroxyl groups could further suppress the neomtimal 
formation. 
Conclusions: This subgroup analysis of ISAR-STEREO-2 shows that restenosis rates 
of the thick-strut Velocity do not differ according to vessel size. The advantage the thin- 
strut stent in this trial, the MultiLink, is for the most part limited to large vessels. This anal- 
ysis suggests that beyond strut thickness, different stent design features may play a dif- 
ferent role dependent on vessel size. 
1150-183 First Use of a Novel Cobalt Chromium Coronary Stent in 
Humans: Clinical and Angiographic Outcomes 
Dean J. Kereiakes, David Alan Cox, James Hermiller, Mark Midei. William Bachlnsky, 
Dean Nukta, Martin Leon, Stanley E. Fink, Linda Marin, Alexandra Lansky, The Lindner 
Center/Ohio Heart Health Center, Cincinnati, OH 
The evolution of an “ideal” stent platform remains critically Important in the era of drug 
eluting stents. Stem strut thickness and alloy may influence device profile, flexibility, 
deliverability, vwbility and radial strength. A novel thin strut (0.0032”) cobalt chromium 
MULTI-LINK (Guidant Corporabon) VISIONTM stent (n=294; lengths 8, 12, 15, 18, 23,28 
mm; diameters 3.0, 3.5, 4.0 mm) was deployed in 267 pabents (age 64 years, 68% male, 
23% diabetes) with a single de now native target vessel lesion k 25 mm length) in a 
multi-center international registry. Anglographic and clinical outcomes for the MULTI- 
LINK VISIONTM stents are compared with those previously observed for the TETRATM 
and PENTATM MULTI-LINK@stents. 
Conclusiorx This novel thin strut cobalt chromium MULTI-LINK VISION TM stent demon- 
strates excellent clinical performance charactenstics with reduced late loss and resteno- 
sis compared with prior MULTI-LINK@ stents. 
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VISlON(n=267) PENTA TETRA 
(n=z!cO) (n=202) 
Lesion length (mm) 10.55 12.90 10.94 
Ref Vessel Diameter 2.94 2.91 2.93 
(mm) 
GP Ilb/llla Use % 53 44 50 
Device success % 100 99 99.5 
Acute Dissection % 0.6 2.5 1.0 
MACE’ (30 days) % 1.9 1.0 2.0 
TVF ** (160 days) % 6.7 9.7 12.8 
Stent Thrombosis at 30 0.4 0.5 0.0 
days % 
Late loss (160 days) 
mm 
0.63 0.90 1.05 
Binary restenosis (180 15.7 
days) % 
17.5 23.6 
*MACE = death, MI. “TVR = death, MI, target site revasc 
target site revasc or target vessel revasc 
1150-184 Randomized Intravascular Ultrasound Comparison 
Between Patients That Underwent Amorphous 
Hydrogenated Silicon-Carbide Coated Stent 
Deployment Versus Uncoated Stents 
Luiz F. Tanajura, Alexandre A. Abizaid, Faust0 Feres, lbraim Pinto, Luiz Mattes, Rodolfo 
St&co, Joao de Paula, Andrea S. Abizaid, Marinella Centernero, Aurea J. Chaves, 
Angela Paes, Ana Seixas, Amanda Sousa, Jose Eduardo M. Sousa, Institute Dante 
Pauanese of Cardiology, Sao Paula, Brazil 
Background: In-stent restenosis remains the the mein limitation of percutaneous coro- 
nary intervention. Amorphous hydrogenated silicon carbide (c&C: H) has been shown 
to reduce the deposition of fibrin. platelets and leukocytes over the stent, improving 
hemocompatibility and biocompatibility. Thus, a-SiC:H coated stents can reduce intimal 
hyperplasia and restenosis. Methods: we conducted a prospective, randomized, open 
label and single center trial to compare the performance of a a-SiC:H coated stent with a 
bare stent in patients with stable and unstable coronary artery disease. We included 100 
patients(50 patients in each group)and the primary end point was in-stent volume of inti- 
mal hyperplasia (IVHI) measured by IVUS. Because stent length was not identical we 
assessed absolute (per patient) and relative (divided per mm of stent length) IVHI. Sec- 
ondary end points included binary restenosis rate, minimal luminal diameter, TVR and 
MACE at six months follow-up. Angiographic patterns of restenosis wers classified 
according to the proposition of Mehran at al. Results: the two groups were similar with 
respect to all variables examined. Procedural success was 100%. At six months, follow- 
up coronary angiography was obtained in 94% of patients in both groups and IVUS was 
performed in 92% of both subsets. Absolute IVHI was greater in a-SiC:H patients (51.2 * 
16.8 mm3 versus 41.9 f 16.4 mn?; p=O.Ol) but relative IVHI was similar (2.9 * 1.0 mm3 
versus 2.5 * 0.9 mm3; p=O.lO). Volume obstruction obtained by IVUS (36.4 * 11.1% ver- 
sus 37.9 * 10.9%; p = 0.29) was also similar. Follow-up minimal luminal diameter (1.9 f 
0.7 versus 1.6 f 0.6 mm; p=O.55), restenosis (19.1 % versus 17%; p=O.99), TVR (16% 
versus 14%; ~~0.99) and MACE (20% versus 16%; pcO.79) occurred similarly. Focal and 
diffuse restenosis were similar. Conclusions: We can conclude: 1) a-SiC:H coating did 
not reduce IVHI, measured by IVUS; 2) follow-up minimal luminal diameter, binary rest- 
enosis, TVR and MACE were similar. 
1150-I 85 Experimental Evaluation of a Novel Balloon Expandable 
Stent and Delivery System for Treatment of Coronary 
Bifurcation Lesions 
Andrew J. Carter, Denise Ambrose, Lori Gibson, Lisa Welch, Leslie Coleman, Renu 
Virmani, Providence Heart Institute, Portland, OR, Aned Forces Institute of Pathology, 
Washington, DC 
Experimental Evaluation of a Novel Balloon Expandable Stent and Delivery System for 
Treatment of Coronary Bifurcation Lesions 
Andrew J. Carter, Denise Ambrose, Lisa Welch, Lori Gibson, Leslie Coleman. Renu Vir- 
mani 
Providence Heart institute, Portland OR: Armed Forces Institute 01 Pathology, Washing- 
ton, DC 
Background: Coronary bifurcation lesions present unique challenges for intracoronety 
stenting despite the adoption of new techniques and also have a higher probability for in- 
stem rastenosis than de nova non-bifurcation lesions. 
Methods: We evaluated the feasibility and biocompatibility of a novel balloon expand- 
able stainless steel bifurcation stent with side-branch aperture support geometry 
mounted on a 7F compatible over-the-wire delivery system (MULTI-LINK FrontierTM) with 
co-axial parent and side-branch “kissing’ balloons, a single inflation port, and separate 
guide wire lumens to preserve vessel access. 
Results: Twenty&de of 25 (100%) bifurcation stents were successfully implanted in the 
coronary arteries of 13 juvenile normolipemic swine in straight (n = 17) or bifurcation (n = 
8) segments. Coronary angiography after implant and at 26-days documented side- 
branch patency in 6 of 6 bifurcation vessels with TIMI- flow. At 26-days. histology dem- 
onstrated mild strut associated inflammation for bifurcation and non-bifurcation implants 
while vessel injury scores tended to be greater in the bifurcation (0.20 f 0.17) as com- 
pared to the non-bifurcation Implants (0.09 * 0.06, p = 0.04). The mean neointimal area, 
however, was similar for the bifurcation (2.60 * 0.6 mm2) and non-bifurcation (2.50 f 
0.70 mm? implants (p = 0.50) which resulted in an equivalent percent area stenosis for 
the stents implanted at a bifurcation (33.7 f 10.7 %) or a non-bifurcation (26.3 f 6.7 %) 
segment (p = 0.23). 
Conclusions: The MULTI-LINK FrontierTM stent and delivery system facilitates treat- 
ment of bifurcation lesions by preserving guide wire position, side-branch access and 
providing stent coverage of the parent vessel and side-branch ostium. Vascular biocom- 
patibility is acceptable in bifurcation and non-bifurcation vessels. 
1150-l 86 A Novel Biodegradable Coronary Polymer Stent With 
Drug Delivery Capacities: Paclitaxel Loading Inhibits 
Neointimal Hyperplasia In a Porcine Model of Coronary 
Restenosis 
Felix Voqt, Andreas Stein, Goesta Rettemeier, Nicole Krott, Rainer Hoffmann, Anja- 
Katrin Bosserhoff, Walter Michaeli. Sasan Habibi-Naini, Ruediger Blindt, University of 
Aachen, Aachen, Germany 
Background: Due to the thrombogenic tendency and permanent implant nature of metal 
stents, synthetic polymers have been proposed as surrogate materials for stems and 
local drug delivery systems. Paclitaxel has been shown to inhibit vascular smooth muscle 
cell proliferation and migration. 
Methods: A novel biodegradable double-helical stent was manufactured using Con- 
trolled Expansion of Saturated Polymers (CESP) for the moulding of a bioresorbable 
poly(D.L)-lactid acid (PDLLA). The whole blood flow Chandler loop model was used for 
testing in vitro hemocompatibility of the stem. In vitro drug release of loaded paclitaxel 
was measured using Enzyme Linked ImmunoSorbent Assay (ELISA). A modified balloon 
catheter for stent deployment was developed according to the mechanical stent proper- 
ties. Six paclitaxel loaded (170 pg/stetent) and 6 unloaded polymer stents were deployed 
in right coronary arteries of domestic pigs (n=12). Sacrification was performed after 3 
weeks. The Cross Section Area (CSA) of the neointima was assessed by histomorpho- 
metric analysis. 
Results: Sufficient in viva hemocompatibility and mechanic stability of the stent and con- 
tinuing drug release of paclitaxel loaded stems for at least one month could be demon- 
strated. Mean CSA of the neointima after paxlitaxel loaded stent implantation was 
reduced by 75% compared to non-loaded stems after 3 weeks (p=O.OOS). 
Concfustons: These results indicate that high-molecular polylactids constitute interest- 
ing materials for polymer stents in combination with new manufacturing techniques. The 
novel polymer stent showed sufficient mechanic stability, and by incorporation of pacli- 
taxel, a significant potential to reduce restenosis development after vascular intervention. 
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1151-173 Relationship Between Right Ventricular Pressure 
Variability and Heart Failure Related Adverse Events 
Philip B. Adamson, Anthony Magalski. Robert C. Bourge, Brandon S. Sparks, Michael R. 
Hill, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Medtronic Inc., 
Minneapolis, MN 
Background: An investigational Implantable Hemodynamic Monitor (IHM) collects con- 
tinuous, ambulatory right ventricular (RV) pressures. The objective of this analysis was to 
determine if RV pressure variability could be used to differentiate heart failure (HF) 
related adverse events. 
Methods: One hundred HF subjects (NYHA class II-IV) were implanted with the IHM 
system. Adverse events were reported on standard case report forms. RV systolic, dias- 
tolic and estimated pulmonary artery diastolic (Epad) pressure data were continuously 
collected by the device and stored in 6 to 24 minute intervals. A daily median pressure 
and daily range (max 94’” percentiles - min 6” percentiles) were derived from these 
intervals. The estimate of within day variability was calculated as the mean of the daily 
RV pressure ranges. The estimate of day-to-day variability was calculated as the stan- 
dard deviation of the daily median RV pressures. Both estimates were calculated from 
data from implantation to study exit or database cutoff. HF Adverse events were related 
to the oressure variabilitv estimates usina Cox Prooortional Hazard’s reoression. 
Results: 62 subjects had at least one heart failure related adverse &ant. The time to 
event ranaed between 0 and 13 months with a mean of two months. Of the 16 subiects 
without an event, follow-up ranged from 1 to 26 months with a mean of 15 months. F&all 
RV pressures, a non-linear relationship (smoothing spline) was found between the risk of 
a HF related event and the mean RV pressure range (p < 0.039 for all). Relatively larger 
or smaller ranges (within day variability) were related to an increased risk of event. For 
diastolic and Epad pressures, as the standard deviation (day-to-day variability) 
increased, so did the risk of an event (p = 0.051, p = 0.074 respectively). 
Conclusions: The variability of RV pressure within days and from day-to-day was 
related to HF adverse events. Subjects with lower day-to-day variability and moderate 
within day variability were at lower risk of HF related adverse events. These results indi- 
cate continuous, ambulatory RV pressure may be a tool that physicians can use to guide 
therapy to better manage patients with HF. 
